سعر سبيراكويت 200مجم 20 اقراص 2025

Quetiapine 200 mg film-coated tablets, pack of 20; Medizen Pharmaceutical Industries, Egypt.

• Schizophrenia.Population: Adults and adolescents 13-17 yearsDailyMed (U.S. National Library of Medicine)
• Bipolar I disorder: acute manic episodes, as monotherapy or adjunct to lithium or divalproex.Population: Adults and children 10-17 years (monotherapy)DailyMed (U.S. National Library of Medicine)
• Bipolar disorder: acute depressive episodes (monotherapy).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Common adverse reactions in adults include somnolence, dry mouth, dizziness, constipation, weight gain, dyspepsia, orthostatic hypotension and increased liver enzymes (see label tables by indication).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to quetiapine or any excipient (anaphylactic reactions reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased mortality in elderly patients with dementia-related psychosis (not approved for this use); suicidal thoughts and behaviours in children, adolescents and young adults.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Metabolic changes (hyperglycaemia/diabetes, dyslipidaemia, weight gain), neuroleptic malignant syndrome, tardive dyskinesia, cerebrovascular events in elderly dementia patients.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Orthostatic hypotension and falls, leukopenia/neutropenia/agranulocytosis, cataracts, QT prolongation, seizures, hypothyroidism, hyperprolactinaemia, cognitive and motor impairment, increased blood pressure in children and adolescents, dysphagia, discontinuation syndrome and anticholinergic effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, nefazodone)Reduce quetiapine dose to one-sixth.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducers (phenytoin, carbamazepine, rifampin, St John's wort)Increase quetiapine up to 5-fold with chronic (more than 7-14 days) use; reduce by 5-fold within 7-14 days of stopping the inducer.DailyMed (U.S. National Library of Medicine)
• Alcohol and other centrally acting drugsPotentiated cognitive and motor effects; limit alcohol.DailyMed (U.S. National Library of Medicine)

• Epidemiologic data have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; there are risks of untreated psychiatric illness. A pregnancy exposure registry exists.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Present in human milk at a relative infant dose below 1% of the maternal weight-adjusted dose; no consistent adverse effects reported in breastfed infants.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.